United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $518.74, for a total value of $4,928,030.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $168,301,561.82. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $532.94 on Friday. The stock has a market cap of $22.62 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 1.74 and a beta of 0.59. The firm’s 50-day moving average is $539.78 and its two-hundred day moving average is $534.19. United Therapeutics Corporation has a 1 year low of $292.34 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the business posted $6.41 EPS. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Quarterly EPS exceeded expectations. United Therapeutics reported second-quarter earnings of $7.27 per share, above the approximately $6.82–$6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a supportive fundamental backdrop. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Ralinepag remains a major potential catalyst. Management highlighted the submission of regulatory applications for ralinepag, while the Phase 3 program and other pipeline developments could diversify growth beyond the company’s established pulmonary hypertension products. Analysts view these milestones as helping offset near-term competitive pressure on Tyvaso. EPS Strength and Ralinepag’s Phase 3 Milestone
• Positive Sentiment: Analysts remain constructive. H.C. Wainwright reiterated a Buy rating with a $660 target, while RBC maintained Outperform despite lowering its target from $704 to $677. The revised RBC target still implies substantial upside based on the quoted market price. Buy Rating Reiterated on United Therapeutics
• Neutral Sentiment: Revenue missed expectations. Second-quarter revenue declined roughly 2% year over year to $783.3 million, below the $804.65 million analyst estimate. The shortfall reflects near-term pressure despite the EPS beat and pipeline progress. United Therapeutics Reports Second-Quarter Results
• Negative Sentiment: Executives disclosed sizable stock sales. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, and EVP Paul Mahon sold 8,300 shares for about $4.3 million. Although these transactions may be scheduled or personal, they represent reductions in insider ownership and can weigh on sentiment.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Leuthold Group LLC boosted its holdings in United Therapeutics by 41.4% during the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares in the last quarter. UBS Group AG increased its holdings in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP increased its holdings in United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after buying an additional 3,766 shares in the last quarter. LBP AM SA acquired a new position in shares of United Therapeutics in the fourth quarter worth about $9,745,000. Finally, M&T Bank Corp raised its position in shares of United Therapeutics by 171.6% in the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after acquiring an additional 1,985 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.